
The weight-loss and type 2 diabetes drug Ozempic (semaglutide) has gained mainstream attention—not only for transformative results like “Ozempic face” or “Ozempic butt,” referring to thinning facial fat and flattening of the derriere—but also for an unexpected side effect: deteriorating dental health. This emerging issue, often referred to as “Ozempic teeth,” describes a pattern of symptoms including tooth decay, sensitivity, enamel loss, gum inflammation, and, in severe cases, tooth loss.
Though “Ozempic teeth” has yet to be formally recognized in medical literature, both patients and practitioners report a noticeable upswing in oral issues among individuals using GLP-1 receptor agonists (like semaglutide and tirzepatide).
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injectable (and in some cases oral) drugs originally developed for type 2 diabetes management. They mimic a natural gut hormone that regulates blood sugar, suppresses appetite, and slows gastric emptying.
Semaglutide—which is marketed as Ozempic (injection) and Wegovy (for weight loss)—along with other GLP-1s such as tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon), have surged in popularity for their potent weight-loss benefits.
Though originally introduced for diabetes control in 2017, GLP-1s’ effectiveness in producing 10–15 percent body weight loss frequently leads to double-digit reductions in body fat and has made them a blockbuster in both weight and metabolic disease therapy.
But their appetite suppression, slowed digestion, and influence on saliva production appear to have unintended effects on oral health.

Dentists and physicians have identified a few interrelated pathways through which GLP-1 medications may increase dental risks:
Probably the most significant contributor. GLP-1 medications can reduce salivary flow and increase the mouth’s stickiness, dramatically lowering saliva’s protective functions.
Saliva’s critical roles include:
When saliva diminishes, plaque accumulates, cavities increase, gum tissues weaken, and halitosis becomes more likely.
GLP-1s commonly cause GI side effects. In clinical trials, 16–20 percent of users on semaglutide experience nausea; five to nine percent report vomiting.
Frequent vomiting and gastroesophageal reflux expose teeth to stomach acid—a potent dissolver of enamel—leading to premature erosion, sensitivity, and increased risk of decay.
Even with significant weight loss, appetite suppression can lead to nutrient deficiencies in minerals and vitamins essential for oral tissues, including vitamin C, D, B-complex, calcium, and zinc.
Chronic lack of these nutrients impairs enamel strength, gum integrity, and recovery from micro-injuries.
Some patients skip brushing, flossing, or attending dental visits when nauseated or fatigued.
Neglect allows plaque to build, accelerating gum disease and cavities.
Case Reports & Expert Observations
Although large-scale clinical trials haven’t yet formally linked GLP-1s with dental outcomes, the wide array of consistent anecdotal and professional reports suggests a real connection.
RELATED: Thinking of Black Market Shopping for Ozempic? Think Again
Be alert to these warning signs if you’re using GLP-1s:
If you observe any of these, early and proactive attention can mean the difference between simple fixes and major restorative work.

Experts emphasize the importance of holistic oral care alongside these medications. Here are detailed prevention tips:
🔹Stay Well Hydrated & Stimulate Saliva
🔹Brush & Floss Wisely
🔹Dietary Balance Matters
🔹Manage GI Symptoms
🔹Professional Dental Care
🔹Avoid Aggravating Factors
RELATED: Surge in Ozempic and Wegovy Prescriptions Could Change Public Health As We Know It
Contact both your dentist and prescribing physician promptly if you experience:
Early intervention often means simpler, less invasive treatment.
To date, GLP-1 medications like Ozempic have not been linked to oral damage in formal clinical trials. But growing evidence—scientific, anecdotal, and clinical—suggests indirect mechanisms at play: reduced saliva, nutrient shifts, reflux, and compromised hygiene routines all contribute.
Larger systematic studies are now emerging. Dental specialists are calling for:
As these medications expand their use, from diabetes to obesity to perhaps even neurocognitive and psychiatric indications, the importance of integrating dental care into treatment plans grows.
GLP-1 medications represent a significant leap forward in managing obesity, diabetes, and possibly other health conditions. They offer reliable, substantial weight loss and metabolic control, with cardiovascular and potential neurological gains.
But like any medication, balancing benefits with potential side effects is key. For many, the oral health impacts are preventable with awareness, planning, and consistent dental self-care.

By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.